[Drug interactions in uro-oncology].
1/5 보강
[BACKGROUND] Modern treatments in uro-oncology are increasingly based on therapeutics with complex metabolism in the human body and are associated with an increased risk of drug interactions.
APA
Husso E, Wittmann M, Zraik IM (2026). [Drug interactions in uro-oncology].. Urologie (Heidelberg, Germany), 65(2), 125-132. https://doi.org/10.1007/s00120-025-02750-y
MLA
Husso E, et al.. "[Drug interactions in uro-oncology].." Urologie (Heidelberg, Germany), vol. 65, no. 2, 2026, pp. 125-132.
PMID
41436653 ↗
Abstract 한글 요약
[BACKGROUND] Modern treatments in uro-oncology are increasingly based on therapeutics with complex metabolism in the human body and are associated with an increased risk of drug interactions.
[OBJECTIVE] This article provides an overview of the most prevalent mechanisms of drug interaction within uro-oncologic therapies and points towards their potential management.
[METHODS] Anti-cancer agents were compiled from the German National Guidelines for the respective indications. Metabolization pathways and potential for drug interactions for those therapeutic drugs as well as the most prevalent drugs for the treatment of concomitant conditions were collected through review of the German prescribing Information (Fachinfo®, www.fachinfo.de ) and an American-based drug information database (uptodate®, www.uptodate.com ). For the most frequent interactions, a pharmaceutical and medical assessment was performed.
[RESULTS] For most anti-cancer agents, metabolization via CYP isoenzymes and transport proteins like p‑glycoprotein play a significant role.
[CONCLUSION] Especially interactions with CYP enzymes like 3A4 are critical as they have potential repercussions on efficacy, safety, and quality of life. Clinical management of concomitant oral anticoagulation or in therapeutically limiting comorbidities (like immunosuppression) are particularly challenging.
[OBJECTIVE] This article provides an overview of the most prevalent mechanisms of drug interaction within uro-oncologic therapies and points towards their potential management.
[METHODS] Anti-cancer agents were compiled from the German National Guidelines for the respective indications. Metabolization pathways and potential for drug interactions for those therapeutic drugs as well as the most prevalent drugs for the treatment of concomitant conditions were collected through review of the German prescribing Information (Fachinfo®, www.fachinfo.de ) and an American-based drug information database (uptodate®, www.uptodate.com ). For the most frequent interactions, a pharmaceutical and medical assessment was performed.
[RESULTS] For most anti-cancer agents, metabolization via CYP isoenzymes and transport proteins like p‑glycoprotein play a significant role.
[CONCLUSION] Especially interactions with CYP enzymes like 3A4 are critical as they have potential repercussions on efficacy, safety, and quality of life. Clinical management of concomitant oral anticoagulation or in therapeutically limiting comorbidities (like immunosuppression) are particularly challenging.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.